Karen Juliana Gonzalez

Ms. Karen Juliana Gonzalez


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
KGKaren Juliana Gonzalez
Karen Juliana Gonzalez
JHJiachen Huang
Jiachen Huang
MCMiria F. Criado
Miria F. Criado
ABAvik Banerjee
Avik Banerjee
Stephen Mark TompkinsStephen Mark Tompkins
Stephen Mark Tompkins
ESEva-Maria Strauch
Eva-Maria Strauch
Many pathogenic viruses rely on class I fusion proteins to fuse their viral membrane with the host cell membrane. To drive the fusion process, class I fusion proteins undergo an irreversible conformational change from a metastable prefusion state to an energetically more stable postfusion state. Mounting evidence underscores that antibodies targeting the prefusion conformation are the most potent, making it a compelling vaccine candidate. Here, we establish a computational design protocol that stabilizes the prefusion state while destabilizing the postfusion conformation. With this protocol, we stabilize the fusion proteins of the RSV, hMPV, and SARS-CoV-2 viruses, testing fewer than a handful of designs. The solved structures of these designed proteins from all three viruses evidence the atomic accuracy of our approach. Furthermore, the humoral response of the redesigned RSV F protein compares to that of the recently approved vaccine in a mouse model. While the parallel design of two conformations allows the identification of energetically sub-optimal positions for one conformation, our protocol also reveals diverse molecular strategies for stabilization. Given the clinical significance of viruses using class I fusion proteins, our algorithm can substantially contribute to vaccine development by reducing the time and resources needed to optimize these immunogens.

13 April 2020 in Biochemistry
Verified
Journal Article
Closed access
HKHyun W. Kim
Hyun W. Kim
AEAlexander Eletsky
Alexander Eletsky
KGKaren Juliana Gonzalez
Karen Juliana Gonzalez
HWHanke van der Wel
Hanke van der Wel
ESEva-Maria Strauch
Eva-Maria Strauch
CWChristopher Mark West
Christopher Mark West

8 July 2021 in Viruses
Verified
Journal Article
Open access
PDF file
YNYogesh Narkhede
Yogesh Narkhede
KGKaren Juliana Gonzalez
Karen Juliana Gonzalez
ESEva-Maria Strauch
Eva-Maria Strauch
The emergence of novel viral infections of zoonotic origin and mutations of existing human pathogenic viruses represent a serious concern for public health. It warrants the establishment of better interventions and protective therapies to combat the virus and prevent its spread. Surface glycoproteins catalyzing the fusion of viral particles and host cells have proven to be an excellent target for antivirals as well as vaccines. This review focuses on recent advances for computational structure-based design of antivirals and vaccines targeting viral fusion machinery to control seasonal and emerging respiratory viruses.

1 April 2020 in Computational Biology and Chemistry
Verified
Journal Article
Closed access
KGKaren Juliana Gonzalez
Karen Juliana Gonzalez
DMDiego M. Moncada-Giraldo
Diego M. Moncada-Giraldo
Juan B. GutiérrezJuan B. Gutiérrez
Juan B. Gutiérrez

2 August 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
KGKaren Juliana Gonzalez
Karen Juliana Gonzalez
ESEva-Maria Strauch
Eva-Maria Strauch
Severe influenza illness or death is a serious concern among the elderly population despite vaccination. To investigate how the adaptive immune response after vaccination varies with the patient’s age, Jung et al., in a recent issue of the JCI, extensively analyzed the serum antibody response in different age groups after immunization with the egg-based influenza vaccine Fluzone. As expected, the immune response in young adults was dominated by antibodies targeting the influenza hemagglutinin (HA) protein. On the contrary, the serological repertoire of elderly donors was characterized by cross-reactive (CR) antibodies recognizing non-HA antigens. Surprisingly, a substantial fraction of these CR antibodies targeted sulfated glycans typical of egg-produced proteins, which does not provide protection against human influenza viruses. Overall, these findings are of great value in understanding suboptimal immunity after influenza vaccination and shaping future vaccine efforts that will achieve increased protection in the elderly.